Extended Data Fig. 4: Clinical and immunologic profile of patient I003 following ESO-T01 infusion.

a, Clinical timeline from Day –1 to Day 19, showing neurologic symptoms and disease progression. The patient developed grade 3 CRS and grade 1 ICANS, ultimately progressing to cardiac arrest and death on Day 19. b, Daily monitoring of temperature and blood pressure, with annotations for corticosteroids (red), tocilizumab (black), norepinephrine (orange), and oxygen support (green; including bi-level positive airway pressure [BIPAP]). c, Serum cytokines (IL-6, IL-8, IL-10) and ferritin showed a biphasic inflammatory profile, with peaks corresponding to CRS episodes. d, Hemoglobin and platelet counts declined, necessitating repeated red blood cell (dark red) and platelet (dark blue) transfusions. e, CAR transgene copies expanded transiently in peripheral blood, accompanied by declines in M protein and FLC λ. These changes may represent transient antitumor activity or immune-related fluctuations, but no durable clinical remission was achieved. Abbreviations: BIPAP, bi-level positive airway pressure; BP, blood pressure; CAR, chimeric antigen receptor; CRS, cytokine release syndrome; FLC, free light chain; ICANS, immune effector cell-associated neurotoxicity syndrome; IL-6, interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10; LOD, limit of detection.